AstraZeneca Receives FDA AdCom Recommendation for Truqap in Prostate Cancer Treatment
AstraZeneca has received a positive recommendation from the FDA's advisory committee for its drug Truqap (capivasertib) as part of a combination therapy for a specific type of prostate cancer. The advisory committee voted 7 to 1 in favor of the drug's use, which could lead to regulatory approval and potential market expansion for the company.
Tickers: $AZN
Topics: AstraZeneca Drug Approval FDA Prostate Cancer Truqap